Precision medicine applications in prostate cancer.

McCrea, Edel M; Lee, Daniel K; Sissung, Tristan M; Figg, William D

McCrea, Edel M; Lee, Daniel K; Sissung, Tristan M; Figg, William D.

Afiliação

McCrea EM; Molecular Pharmacology Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Lee DK; Medical Oncology Service, and the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Sissung TM; Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Figg WD; Clinical Pharmacology Program, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville Pike, Bldg 10/Room 5A01, Bethesda, MD 20892, USA.

Ther Adv Med Oncol ; 10: 1758835918776920, 2018.

Article em En | MEDLINE | ID: mdl-29977347

Palavras-chave

AR-V7; androgen deprivation therapy resistance; microsatellite instability; organic anion transporting polypeptide 1B3; precision medicine; sex determining region Y box2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google